Hemispherx Biopharma Inc (NYSE MKT LLC:HEB)

0.2349
Delayed Data
As of May 21
 -0.0041 / -1.72%
Today’s Change
0.21
Today|||52-Week Range
0.40
-6.04%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$55.6M

Company Description

Hemispherx Biopharma, Inc. is a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Philadelphia, PA.

Contact Information

Hemispherx Biopharma, Inc.
One Penn Center
Philadelphia Pennsylvania 19103
P:(215) 988-0080
Investor Relations:

Employees

Shareholders

Other institutional3.33%
Mutual fund holders2.99%
Individual stakeholders2.35%

Top Executives

William A. CarterChairman, President, Chief Executive Officer & CSO
Wayne S. SpringateSenior Vice President-Operations
Thomas Kenwood EquelsExecutive Vice Chairman, CFO & Secretary
David R. StrayerCMO, Medical Director & Head-Regulatory Affairs
Ralph Christopher CavalliVice President-Quality Control

To view my watchlist

Not a member yet?

Sign up now for a free account